Kong, Qihui Gao, Nanyong Wang, Yahui Hu, Guoxin Qian, Jianchang Chen, Bingbing
Published in
Frontiers in Pharmacology
The aim of this study is to investigate the effects of CYP3A4 genetic polymorphisms on the metabolism of cyclosporine (CsA) in vitro and identify drugs that interact with CsA. An enzymatic incubation system was developed to evaluate the kinetic parameters of CYP3A4 on CsA catalysis. A total of 132 drugs were screened to identify potential drug–drug...
Krapfl, Aaron McLeod, Caleb Myers, Rebecca Venugopal, Parameswaran Seddon, Amanda
Published in
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Chronic lymphocytic leukemia (CLL) is commonly treated with the B-cell lymphoma 2 inhibitor (BCL-2) venetoclax. Venetoclax is associated with an increased risk of tumor lysis syndrome in this patient population. Because venetoclax undergoes CYP3A4 metabolism, strong CYP3A4 inhibitors are contraindicated during the ramp-up phase of venetoclax in pat...
Tuey, Stacey M Prebehalla, Linda Roque, Amandla-Atilano Roda, Gavriel Chonchol, Michel B Shah, Nirav Wempe, Michael F Hu, Yichun Hogan, Susan L Nolin, Thomas D
...
Published in
Journal of clinical pharmacology
The aim of this study was to investigate the impact of suboptimal 25-hydroxyvitamin D (25-VitD) and cholecalciferol (VitD3 ) supplementation on the pharmacokinetics of oral midazolam (MDZ) in control subjects and subjects with chronic kidney disease (CKD). Subjects with CKD (n = 14) and controls (n = 5) with suboptimal 25-VitD levels (3 (5000 IU) a...
Sun, Sen Liu, Lu Song, Hongming Li, Hong
Published in
Pharmaceutical biology
The co-administration of abemaciclib and astragaloside IV might occur in the treatment of breast cancer. This study evaluates the interaction between abemaciclib and astragaloside IV in rats and describes the potential mechanism. Male Sprague Dawley rats were randomly divided into four groups: single dose of abemaciclib (control), abemaciclib + 50 ...
Asakawa, Riko Ogawa, Youichi Maejima, Eri Honobe-Tabuchi, Akiko Okamoto, Takashi Mitsui, Hiroshi Kagawa, Yoshiyuki Shimada, Shinji Kawamura, Tatsuyoshi
Published in
The Journal of dermatology
The most common treatment option for patients with bullous pemphigoid is systemic corticosteroids. CYP3A4, a drug-metabolizing enzyme in the liver, metabolizes synthetic steroids to a varying degree. Although there are many CYP3A4-inducing drugs, several antiepileptic drugs, such as phenytoin and phenobarbital, strongly induce CYP3A4, thereby reduc...
Wang, Li Wu, Fan Xu, Jia Wang, Yu Fei, Weidong Jiang, Hui Geng, Peiwu Zhou, Quan Wang, Shuanghu Zheng, Yongquan
...
Published in
Frontiers in Pharmacology
It has been reported that drug-drug interactions (DDIs) can affect the pharmacokinetics and pharmacodynamics of various oral drugs. To better understand the effects of azole antifungal drugs (ketoconazole, fluconazole, and itraconazole) on pyrotinib’s pharmacokinetics, DDIs between pyrotinib and three azoles were studied with Sprague-Dawley (SD) ra...
Šimičević, Livija Canjuga, Iva Zibar, Lada Borić-Bilušić, Ana Ganoci, Lana Božina, Nada
Published in
Journal of clinical pharmacy and therapeutics
Tacrolimus (TAC) is an immunosuppressant with large interpatient pharmacokinetic variability and a narrow therapeutic index. We report a case of acute cellular rejection (ACR) type IB with insufficient TAC blood concentrations (TAC C0 ). ACR developed on the eighth postoperative day of kidney transplantation. During this period, TAC C0 were insuffi...
Zhao, Tingting Li, Xuening Chen, Yanwei Du, Jie Chen, Xiaodong Wang, Dalong Wang, Liyan Zhao, Shan Wang, Changyuan Meng, Qiang
...
Published in
Frontiers in Pharmacology
Cancer patients generally has a high risk of thrombotic diseases. However, anticoagulant therapy always aggravates bleeding risks. Rivaroxaban is one of the most widely used direct oral anticoagulants, which is used as anticoagulant treatment or prophylaxis in clinical practice. The present study aimed to systemically estimate the combination safet...
Tantawy, Marwa Collins, Joseph M. Wang, Danxin
Published in
Frontiers in Pharmacology
Cytochrome P450 (CYP) drug metabolizing enzymes are responsible for the metabolism of over 70% of currently used medications with the CYP3A family being the most important CYP enzymes in the liver. Large inter-person variability in expression/activity of the CYP3As greatly affects drug exposure and treatment outcomes, yet the cause of such variabil...
Niwa, Toshiro Ishii, Risa
Published in
Drug metabolism and bioanalysis letters
The mechanism-based inhibition of macrolide antibiotics, such as erythromycin and clarithromycin, and piperine on testosterone 6β-hydroxylation activities by cytochrome P450 (CYP) 3A4, polymorphically expressed CYP3A5, and fetal CYP3A7 were compared. 6β-Hydroxy testosterone was determined by high-performance liquid chromatography. Although preincub...
